All In Biotech

Free tool

FAERS Monitor: Opvee

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217470 or its brand name (Opvee, Nalmefene Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

43

Serious

35

81% of reports

Hospitalization

16

Death reported

10

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • coma5
  • therapy non-responder5
  • bradycardia4
  • bradypnoea4
  • electrocardiogram qt prolonged4
  • hypothermia4
  • intentional overdose4
  • miosis4
  • pneumonia aspiration4
  • diabetic ketoacidosis3
  • drug withdrawal syndrome3
  • nausea3
  • off label use3
  • pulmonary oedema3
  • sudden death3

Reports by year received

View as table
YearReports
20041
20053
20103
20131
20143
20151
20171
20185
20221
20232
20247
202511
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,116 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bradypnoeaSignal4726.2285.42,214
miosisSignal4243.995.9740
hypothermiaSignal4193.376.0585
sudden deathSignal3138.746.6284
pneumonia aspirationSignal478.330.8233
diabetic ketoacidosisSignal361.120.5122
therapy non-responderSignal554.423.9212
electrocardiogram qt prolongedSignal454.421.4160
comaSignal551.422.5200
bradycardiaSignal436.914.5106
pulmonary oedemaSignal332.811.064
intentional overdoseSignal430.512.087
drug withdrawal syndromeSignal316.75.630
nausea31.90.60
off label use31.70.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.